An observational study in Mediastinitis, sponsored by Pierre Wauthy. Completed at 1 site in Belgium. Per ClinicalTrials.gov, last updated 2019-07-16.
Sponsored by Pierre Wauthy · Observational
Mediastinitis is an infectious complication that can occur after cardiac surgery. The incidence varies between 1 and 3% depending on the type of procedure and the patient's condition. The mortality of this severe postoperative complication rises from 10 to 35%, which makes it dreadful.
The major risk factors reported are obesity, diabetes, and immunosuppressive therapy. There are other less important ones: age, coronary bypass grafting (especially if using the two internal mammary arteries), nosocomial pneumonia, dialysis, prolonged mechanical ventilation, long operative asepsis, undrained retro-sternally hematoma, prolonged pre-operative hospitalization...).
Prevention is very important. The principle of asepsis must absolutely be respected. The use of prophylactic antibiotic therapy is recommended.
The most commonly encountered organisms are Staphylococcus aureus, coagulase-negative Staphylococci and gram-negative bacilli.
There are several treatment modalities that vary between centers and may be different depending on the surgical team's experience and the depth or extent of the infection. The common principles of these treatments are: antibiotic therapy and surgical debridement (the timing of which may vary). The timing and modalities of wound closure are subject to variations: immediate sternal closure with placement of multiple or delayed drains. Muscle flaps or large omentum transplant may be necessary if tissue loss is too important.
The investigators propose to review their experience in the treatment of cardiac post-surgery mediastinitis at Brugmann University Hospital in the last 20 years in both adult and pediatric patients.
21 studies on the registry are indexed under Mediastinitis; 3 are open to participants now.
Browse Mediastinitis studies →Pierre Wauthy is the lead sponsor of 12 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients of the CHU Brugmann (adults) and HUDERF (pediatric) Hospitals, treated for post-cardiac surgery mediastinitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Infants diagnosed with cardiac post-surgery mediastinitis within the HUDERF Hospital within the last 20 years.
Other: Data extraction from medical files
Adults diagnosed with cardiac post-surgery mediastinitis within the CHU Brugmann Hospital within the last 20 years.
Other: Data extraction from medical files
Data extraction from medical files
Duration of the hospitalization
Duration of the hospitalization
Time frame: 20 years
Mortality at six months
Mortality rate six months after mediastinitis diagnosis
Time frame: 6 months
Percentage of recurrence
Percentage of recurrence of mediastinitis
Time frame: 20 years
Percentage of re-hospitalization
Percentage of re-hospitalizations caused by mediastinitis
Time frame: 20 years
Duration of the antibiotic treatment
Duration of the antibiotic treatment for mediastinitis
Time frame: 20 years
Presence of superinfection
Presence of superinfection
Time frame: 20 years
Date of birth
Demographic data : Date of birth.
Time frame: 20 years
Sex
Demographic data : sex.
Time frame: 20 years
Risk factors
Demographic data : presence of risk factors (obesity, diabetes...).
Time frame: 20 years
Surgical intervention
Name of the surgical intervention that caused the mediastinitis
Time frame: 20 years
Germ identification
Name of the germ causing the mediastinitis
Time frame: 20 years
Type of treatment
Name of the antibiotics used to treat the mediastinitis
Time frame: 20 years
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pierre Wauthy